Opinion|Videos|April 18, 2025
Closing Insights: The Future of Cemiplimab in NSCLC and Beyond
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As new data on cemiplimab and other checkpoint inhibitors continue to emerge, how do you anticipate the overall treatment pathway for cancers like NSCLC will change?
Advertisement
Related to this article
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
8 takeaways from the MHE and Drug Topics post-midterms webinar
3
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
4
On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
5